G Monteleone

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. ncbi Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis
    Giovanni Monteleone
    Universita Tor Vergata, Dipartimento di Medicina Interna, Via Montpellier, 1, 00133 Rome, Italy
    Curr Opin Investig Drugs 8:423-8. 2007
  2. ncbi Role of Smad7 in inflammatory bowel diseases
    Giovanni Monteleone
    Department of Internal Medicine, University Tor Vergata of Rome, 00133 Rome, Italy
    World J Gastroenterol 18:5664-8. 2012
  3. ncbi The dual role of inflammation in colon carcinogenesis
    Giovanni Monteleone
    Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy E Mails G M F P
    Int J Mol Sci 13:11071-84. 2012
  4. ncbi Interleukin-21 in immune and allergic diseases
    Massimiliano Sarra
    Dipartimento di Medicina Interna, Università Tor Vergata of Rome, Rome, Italy
    Inflamm Allergy Drug Targets 11:313-9. 2012
  5. ncbi Th17-related cytokines in inflammatory bowel diseases: friends or foes?
    I Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
    Curr Mol Med 12:592-7. 2012
  6. ncbi Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease
    Giovanni Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    Mol Ther 20:870-6. 2012
  7. ncbi Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages
    Angelamaria Rizzo
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Inflamm Bowel Dis 18:449-59. 2012
  8. ncbi Bacteria and mucosal immunity
    Giovanni Monteleone
    Department of Internal Medicine, Gastroenterology Unit, Tor Vergata University, Rome, Italy
    Dig Liver Dis 38:S256-60. 2006
  9. ncbi New mediators of immunity and inflammation in inflammatory bowel disease
    Giovanni Monteleone
    Department of Internal Medicine, Centre of Excellence for the Study of Genomic Risk in Complex and Multifactorial Pathology, Tor Vergata University of Rome, Rome, Italy
    Curr Opin Gastroenterol 22:361-4. 2006
  10. ncbi Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease
    Giovanni Monteleone
    Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00133, Rome, Italy
    Cytokine Growth Factor Rev 20:185-91. 2009

Collaborators

Detail Information

Publications96

  1. ncbi Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis
    Giovanni Monteleone
    Universita Tor Vergata, Dipartimento di Medicina Interna, Via Montpellier, 1, 00133 Rome, Italy
    Curr Opin Investig Drugs 8:423-8. 2007
    ..By July 2004, phase III trials for ulcerative colitis had been initiated in Japan and phase II studies were ongoing in Europe and the U.S.; this remained the case in May 2006...
  2. ncbi Role of Smad7 in inflammatory bowel diseases
    Giovanni Monteleone
    Department of Internal Medicine, University Tor Vergata of Rome, 00133 Rome, Italy
    World J Gastroenterol 18:5664-8. 2012
    ..In this article we review the available data supporting the pathogenic role of Smad7 in IBD and discuss whether and how Smad7 antisense therapy could help dampen the ongoing inflammation in IBD...
  3. ncbi The dual role of inflammation in colon carcinogenesis
    Giovanni Monteleone
    Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy E Mails G M F P
    Int J Mol Sci 13:11071-84. 2012
    ..This review outlines the beneficial and detrimental role of inflammation in colon carcinogenesis...
  4. ncbi Interleukin-21 in immune and allergic diseases
    Massimiliano Sarra
    Dipartimento di Medicina Interna, Università Tor Vergata of Rome, Rome, Italy
    Inflamm Allergy Drug Targets 11:313-9. 2012
    ..The demonstration that IL-21 is involved in the immune responses occurring in chronic inflammatory and allergic diseases suggests that either disrupting or enhancing IL-21 signalling may be useful in specific clinical settings...
  5. ncbi Th17-related cytokines in inflammatory bowel diseases: friends or foes?
    I Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
    Curr Mol Med 12:592-7. 2012
    ..g. TGF-β1) or inflammatory (e.g. IL-12, IL-23) cytokines have contributed to advance our understanding of mechanisms that regulate mucosal homeostasis and inflammation in the gut...
  6. ncbi Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease
    Giovanni Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    Mol Ther 20:870-6. 2012
    ..GED0301 treatment reduced the percentage of inflammatory cytokine-expressing CCR9-positive T cells in the blood. The study shows for the first time that GED0301 is safe and well tolerated in patients with active CD...
  7. ncbi Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages
    Angelamaria Rizzo
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Inflamm Bowel Dis 18:449-59. 2012
    ..Since Th2-cytokines can abrogate inflammatory pathways by inducing alternatively activated macrophages (AAMs), we evaluated whether AAMs are involved in the IL-25-mediated anticolitic effect...
  8. ncbi Bacteria and mucosal immunity
    Giovanni Monteleone
    Department of Internal Medicine, Gastroenterology Unit, Tor Vergata University, Rome, Italy
    Dig Liver Dis 38:S256-60. 2006
    ..Emerging evidence also indicates that gut microflora can contribute to maintain the mucosal homeostasis by promoting the generation and/or expansion of counter-regulatory mechanisms...
  9. ncbi New mediators of immunity and inflammation in inflammatory bowel disease
    Giovanni Monteleone
    Department of Internal Medicine, Centre of Excellence for the Study of Genomic Risk in Complex and Multifactorial Pathology, Tor Vergata University of Rome, Rome, Italy
    Curr Opin Gastroenterol 22:361-4. 2006
    ..This review summarizes current knowledge regarding the role of immune-inflammatory mediators in the pathogenesis of inflammatory bowel disease...
  10. ncbi Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease
    Giovanni Monteleone
    Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00133, Rome, Italy
    Cytokine Growth Factor Rev 20:185-91. 2009
    ..Here we describe the emerging role of IL-21 in the initiation and progress of the tissue-damaging inflammatory response in immune-mediated pathologies...
  11. ncbi Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses
    Giovanni Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome 00133, Italy
    Trends Immunol 29:290-4. 2008
    ....
  12. ncbi TGF-beta1 and Smad7 in the regulation of IBD
    G Monteleone
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Mucosal Immunol 1:S50-3. 2008
    ..These data support a role for Smad7 in maintaining intestinal inflammation, and suggest that blocking Smad7 could be a promising way to dampen the ongoing inflammation in IBD...
  13. ncbi Interleukin-21 as a new therapeutic target for immune-mediated diseases
    Giovanni Monteleone
    Department of Internal Medicine, University of Rome Tor Vergata, Rome 00133, Italy
    Trends Pharmacol Sci 30:441-7. 2009
    ....
  14. ncbi IL-23/IL-17 axis in IBD
    Massimiliano Sarra
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Inflamm Bowel Dis 16:1808-13. 2010
    ..We here review the available data regarding the role of Th17 cells and IL-23 in chronic intestinal inflammation...
  15. ncbi Interleukin-25: a two-edged sword in the control of immune-inflammatory responses
    Giovanni Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Cytokine Growth Factor Rev 21:471-5. 2010
    ....
  16. ncbi Psoriasis: from pathogenesis to novel therapeutic approaches
    Giovanni Monteleone
    Gastroenterology Unit, Internal Medicine Department, University Tor Vergata of Rome, 00133 Rome, Italy
    Clin Sci (Lond) 120:1-11. 2011
    ..Understanding the immunology of the psoriatic plaque has led to new therapeutic options and novel candidates for immunomodulation, and has changed the ways psoriatic patients are managed...
  17. ncbi Th17-related cytokines: new players in the control of chronic intestinal inflammation
    Ivan Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, Rome, Italy
    BMC Med 9:122. 2011
    ..These novel findings have contributed to advancing our understanding of mechanisms of gut tissue damage and open new avenues for development of therapeutic strategies in IBD...
  18. ncbi Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21
    G Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Gut 55:1774-80. 2006
    ..We have previously shown that, in IBD, there is high production of interleukin (IL) 21, a T cell-derived cytokine, which enhances Th1 activity...
  19. ncbi Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease
    Giovanni Monteleone
    Department of Internal Medicine and Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University of Tor Vergata, Rome, Italy
    Gastroenterology 129:1420-9. 2005
    ..In this study, we examined the molecular mechanism underlying the induction of Smad7 in the human gut...
  20. ncbi Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease
    Giovanni Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Gastroenterology 128:687-94. 2005
    ..In this study, we examined the expression and role of IL-21, a T-cell-derived cytokine of the IL-2 family; in tissues and cells isolated from patients with inflammatory bowel disease...
  21. ncbi Smad7 in TGF-beta-mediated negative regulation of gut inflammation
    Giovanni Monteleone
    Department of Internal Medicine and Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, Cattedra di Gastroenterologia, University Tor Vergata of Rome, Italy
    Trends Immunol 25:513-7. 2004
    ....
  22. ncbi A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation
    Giovanni Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome 00133, Italy
    J Biol Chem 279:3925-32. 2004
    ..These data show that TGF-beta1 is a negative regulator of NF-kappaB activation in the gut and that Smad7 maintains high NF-kappaB activity in gut inflammation by blocking TGF-beta1 signaling...
  23. ncbi T-cell-directed therapies in inflammatory bowel diseases
    Giovanni Monteleone
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Clin Sci (Lond) 118:707-15. 2010
    ..In the present article, we review the available results showing that T-cell-directed therapies are useful to dampen the tissue-damaging immune response in IBDs...
  24. ncbi Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells
    G Monteleone
    Dipartimento di Medicina Interna, Cattedra di Gastroenterologia e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, University Tor Vergata of Rome, Rome, Italy
    Cell Death Differ 13:202-11. 2006
    ..Finally, we show that 5-ASA attenuates p-EGFR in ex vivo organ cultures of CRC explants. Data indicate that 5-ASA disrupts EGFR signalling by enhancing SH-PTP2 activity, and suggest a mechanism by which 5-ASA interferes with CRC growth...
  25. ncbi Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection
    Giovanni Monteleone
    Department of Internal Medicine and Center for Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University Tor Vergata, Rome, Italy
    Gastroenterology 126:674-82. 2004
    ..Transforming growth factor (TGF)-beta 1 negatively regulates Th1 cell development, and TGF-beta 1-deficient mice spontaneously develop gastritis. Here, we examined TGF-beta 1 signaling in Hp-associated gastritis...
  26. ncbi Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa
    I Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Gut 53:1090-5. 2004
    ..In coeliac disease (CD) mucosa, the histological lesion is associated with marked infiltration of T helper cell type 1 (Th1) cells. However, the molecular mechanisms which regulate Th1 cell differentiation in CD mucosa are unknown...
  27. ncbi Emerging immunological targets in inflammatory bowel disease
    Giovanni Monteleone
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Curr Opin Pharmacol 11:640-5. 2011
    ..The clarification of the complex networks of immune-inflammatory mediators operating in the gut of IBD patients has led to the identification of new targets that should facilitate the development of novel biological therapies...
  28. ncbi Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease
    D Fina
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universitè Tor Vergata, Rome, Italy
    Gut 57:887-92. 2008
    ..However, the molecular mechanisms which regulate T-bet and promote the Th1 cell response are unknown...
  29. ncbi IL-21 comes of age as a regulator of effector T cells in the gut
    M C Fantini
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Mucosal Immunol 1:110-5. 2008
    ..Overall, there is now sufficient evidence to suggest that targeting IL-21 will be of therapeutic benefit in IBD...
  30. ncbi Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation
    F Caprioli
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Gut 57:1674-80. 2008
    ..This phenomenon has been functionally linked with the elevated expression of Flip, an inhibitor of Fas-mediated apoptosis. In this study, the molecular mechanisms that control Flip in CD were examined...
  31. ncbi Interleukin-25 production is differently regulated by TNF-α and TGF-β1 in the human gut
    D Fina
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Mucosal Immunol 4:239-44. 2011
    ..Knockdown of Smad7 was accompanied by an increase in IL-25 production. Data show that IL-25 production is differently regulated by TNF-α and TGF-β1 in the human gut...
  32. ncbi Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut
    Roberta Caruso
    Department of Internal Medicine and Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University Tor Vergata of Rome, Rome, Italy
    Gastroenterology 136:2270-9. 2009
    ..Because Th1 and Th2 cells, and the cytokines they release, are often mutually antagonistic, we examined whether IL-25 affects IL-12 production or Th1 cell-mediated inflammation in the gut...
  33. ncbi Autocrine regulation of IL-21 production in human T lymphocytes
    Flavio Caprioli
    Department of Internal Medicine, University Tor Vergata, Via Montpellier 1, Rome, Italy
    J Immunol 180:1800-7. 2008
    ..These data suggest the existence of a positive autocrine loop that could help to amplify and stabilize IL-21-driven, T cell-mediated responses...
  34. ncbi Immunoregulation in the gut: success and failures in human disease
    I Monteleone
    , Dipartimento di Medicina Interna, , Vergata, Roma, Italy
    Gut 50:III60-4. 2002
    ..Despite this, CD and UC share downstream inflammatory events, characterised by high levels of inflammatory cytokines, free radicals, matrix-degrading enzymes and growth factors...
  35. ncbi Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis
    Roberta Caruso
    Gastroenterology, University Tor Vergata of Rome, Rome, Italy
    Nat Med 15:1013-5. 2009
    ..In the human psoriasis xenograft mouse model, blockade of IL-21 activity resolves inflammation and reduces keratinocyte proliferation. Blocking IL-21 may represent a new therapeutic strategy in psoriasis...
  36. ncbi IL-15 positively regulates IL-21 production in celiac disease mucosa
    M Sarra
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Mucosal Immunol 6:244-55. 2013
    ..Similarly, neutralization of IL-15 in biopsies of inactive CD patients inhibited peptic-tryptic digest of gliadin-induced IL-21 expression. These findings indicate that in CD, IL-15 positively regulates IL-21 production...
  37. ncbi A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells
    Roberta Caruso
    Dipartimento di Medicina Interna e Centro di Eccellenza, Studio delle Malattie Complesse e Multifattoriali, Universita Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Gastroenterology 132:166-75. 2007
    ..In this study we examined whether intestinal epithelial cells express IL-21R and respond to IL-21 in IBD...
  38. ncbi Regulation of gut inflammation and th17 cell response by interleukin-21
    Daniele Fina
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome
    Gastroenterology 134:1038-48. 2008
    ..We here examined whether IL-21 is necessary for the initiation and progress of experimental colitis and whether it regulates specific pathways of inflammation...
  39. ncbi The dual role of interleukin-25 in the control of immune-mediated pathologies
    R Caruso
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    Curr Mol Med 11:26-30. 2011
    ..These new and exciting observations reveal a broader role for IL-25 than previously anticipated, and delineate various scenarios where therapeutic interventions around IL-25 activity can be imagined...
  40. ncbi Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus
    Massimiliano Sarra
    Department of Internal Medicine, University Tor Vergata of Rome, 00133 Rome, Italy
    J Biomed Biotechnol 2010:294582. 2010
    ..Here we review data supporting the involvement of IL-21 in the pathogenesis of SLE...
  41. ncbi Characterization of IL-17A-producing cells in celiac disease mucosa
    Ivan Monteleone
    Dipartimento di Medicina Interna, Universita Tor Vergata, Rome, Italy
    J Immunol 184:2211-8. 2010
    ..In conclusion, our data show that IL-17A is increased in CD and is produced by cells that also make IFN-gamma...
  42. ncbi Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression
    Massimo C Fantini
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Gastroenterology 136:1308-16, e1-3. 2009
    ..In this study, we have investigated whether IBD mucosal CD4+ T cells are resistant to Tregs and whether Smad7 is involved in this process...
  43. ncbi IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis
    Roberta Caruso
    Department of Internal Medicine and Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University of Rome Tor Vergata, Rome, Italy
    J Immunol 178:5957-65. 2007
    ..These data indicate that IL-21 is overexpressed in Hp-infected gastric mucosa where it could contribute to increased epithelial gelatinase production...
  44. ncbi Interleukin-21 triggers effector cell responses in the gut
    Daniela De Nitto
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    World J Gastroenterol 16:3638-41. 2010
    ..In this article, we review the available data supporting the pathogenic role of IL-21 in IBD...
  45. ncbi CARD15 mutation analysis in an Italian population: Leu1007fsinsC but neither Arg702Trp nor Gly908Arg mutations are associated with Crohn's disease
    Piero Vavassori
    Cattedra di Gastroenterologia, Centro d eccellenza per lo studio del rischio genomico in patologie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Inflamm Bowel Dis 10:116-21. 2004
    ..The purpose of this study was to evaluate the frequency of the main mutations of the CARD15 gene (Leu 1007fsinsC, Arg702Trp, and Gly908Arg) in Italian CD patients and to establish possible genotype-phenotype correlations...
  46. ncbi A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn’s disease
    F Zorzi
    Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
    Aliment Pharmacol Ther 36:850-7. 2012
    ....
  47. ncbi Contraindications for whole body vibration training: a case of nephrolitiasis
    G Monteleone
    Department of Surgery, Faculty of Medicine and Surgery, Tor Vergata University, Rome, Italy
    J Sports Med Phys Fitness 47:443-5. 2007
    ..This paper reports a case of significant morbidity following one session of WBV training in a patient with asymptomatic nephroli-thiasis...
  48. ncbi Resting metabolic rate incremented by pulsating electrostatic field (PESF) therapy
    A De Lorenzo
    Division of Human Nutrition, Department of Neurosciences, Faculty of Medicine and Surgery, Fondazione Salus Onlus Trasacco, Tor Vergata University, Rome, Italy
    Diabetes Nutr Metab 17:309-12. 2004
    ..After PESF therapy, the average RMR (measured by indirect calorimetry) of 1255 kcal was increased on average by 323 kilocalories, indicating a possible role of PESF in the obesity treatment...
  49. ncbi The Viladot-Regnauld operation for hallux valgus
    G Monteleone
    Dipartimento di Chirurgia, Sezione di Ortopedia e Traumatologia, Universita degli Studi di Roma Tor Vergata, Via di Tor Vergata, 135, 000133 Rome, Italy
    Int Orthop 27:36-9. 2003
    ..Sesamoids were medialised, on average, by at least 25% compared to the pre-operative situation. The results confirm the validity of this surgical procedure...
  50. ncbi Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies
    Massimo C Fantini
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    World J Gastroenterol 15:2472-8. 2009
    ..Finally, accumulating evidence indicates that a T helper 17 cell-mediated immune response may contribute to IBD and IBD-related SpA with a crucial role played by tumor necrosis factor-alpha in CD and to a lesser extent in UC...
  51. ncbi IL-21 in the pathogenesis and treatment of skin diseases
    Antonio Costanzo
    Dermatology Unit, Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
    J Dermatol Sci 60:61-6. 2010
    ..Here we review recent advancements on the understanding of the role of IL-21 in skin diseases and how this knowledge can be translated into innovative therapeutic approaches...
  52. ncbi IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells
    Massimo C Fantini
    Division of Gastroenterology, University of Rome Tor Vergata, Rome, Italy
    Eur J Immunol 37:3155-63. 2007
    ..Therefore, IL-21 emerges as a key modulator of TGF-beta signaling, leading to the reciprocal differentiation of T(reg) and Th17 cells...
  53. ncbi Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation
    Ilaria Peluso
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Infect Immun 75:1730-7. 2007
    ..The data show that L. paracasei subsp. paracasei B21060 blocks T-cell growth, thus suggesting a mechanism by which these probiotics could interfere with T-cell-driven immune responses...
  54. ncbi Targeting interleukin-21 in immune-mediated pathologies
    Massimiliano Sarra
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Curr Drug Targets 11:645-9. 2010
    ..Here we review the present knowledge on the expression and role of IL-21 in immune-mediated pathologies...
  55. ncbi New players in the cytokine orchestra of inflammatory bowel disease
    Massimo C Fantini
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Inflamm Bowel Dis 13:1419-23. 2007
    ..Two other cytokines, IL-27 and IL-32, may also be important in the inflammatory pathways that operate in IBD...
  56. ncbi Role of IL-21 in inflammatory bowel disease
    Francesco Pallone
    Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Expert Rev Clin Immunol 6:537-41. 2010
    ....
  57. ncbi Genetic and pathogenetic insights into inflammatory bowel disease
    Francesco Pallone
    Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Universita Tor Vergata di Roma, Via Monpellier 1, 00133 Rome, Italy
    Curr Gastroenterol Rep 5:487-92. 2003
    ....
  58. ncbi Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases
    Massimiliano Sarra
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Inflamm Bowel Dis 16:1332-9. 2010
    ..However, the phenotype of IL-21-producing cells in IBD, and the cytokine(s) they coproduce, is not known. We here characterized the cell source of IL-21 and determined which factors regulate IL-21 in the human gut...
  59. ncbi Interleukin-21 (IL-21) controls inflammatory pathways in the gut
    Daniele Fina
    Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
    Endocr Metab Immune Disord Drug Targets 7:288-91. 2007
    ..These data collectively indicate that IL-21 is a mediator of the chronic inflammatory response in CD and UC, and suggest that IL-21 may be an emerging therapeutic target in IBD...
  60. ncbi IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa
    Roberta Caruso
    Department of Internal Medicine and Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University Tor Vergata of Rome, Rome, Italy
    Eur J Immunol 38:470-8. 2008
    ..Data show that IL-23 is overexpressed in Hp-infected gastric mucosa where it could contribute to sustaining IL-17 production...
  61. ncbi Interleukin-23 and Th17 cells in the control of gut inflammation
    Ivan Monteleone
    Department of Internal Medicine, University Tor Vergata of Rome, 00133 Rome, Italy
    Mediators Inflamm 2009:297645. 2009
    ..In this review, we discuss the available data supporting the role of the IL-23/Th17 axis in the modulation of intestinal tissue inflammation...
  62. ncbi IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes
    Ilaria Peluso
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier 1, Rome, Italy
    J Immunol 178:732-9. 2007
    ..Data indicate that IL-21 renders human CD4(+)CD25(-) T cells resistant to Treg-mediated suppression and suggest a novel mechanism by which IL-21 could augment T cell-activated responses in human immune-inflammatory diseases...
  63. ncbi Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase
    Carmine Stolfi
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Carcinogenesis 29:1258-66. 2008
    ..Data show that mesalazine negatively regulates CDC25A protein expression, thus delaying CRC cell progression...
  64. ncbi Interleukin-21 in T cell-mediated diseases
    Giovanni Monteleone
    Internal Medicine, University of Rome Tor Vergata, Rome 00133, Italy
    Discov Med 8:113-7. 2009
    ..Here we review the present knowledge on the expression and role of IL-21 in T cell-mediated pathologies...
  65. ncbi The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway
    Barbara Marinari
    Departments of Dermatology and Gastroenterology, University of Rome Tor Vergata, 00133 Rome, Italy
    Proc Natl Acad Sci U S A 105:17091-6. 2008
    ..These results suggest that the tumor-suppressive activity of IKKalpha in stratified epithelia may be exerted in part via the TGF-beta signaling pathway...
  66. ncbi A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis
    Ivan Monteleone
    Dipartimento di Medicina Interna e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, Universita Tor Vergata, Rome, Italy
    Gastroenterology 130:389-97. 2006
    ..In this study we examined the functional role of Flip, a Flice inhibitor protein, in the resistance of CD LPL to FAS-mediated apoptosis...
  67. ncbi Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis
    Monica Boirivant
    Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanit, Rome, Italy
    Gastroenterology 131:1786-98. 2006
    ..This may represent a new approach to the control of IBD, particularly during active phases when its Smad7 profile resembles that of hapten-induced colitis...
  68. ncbi Collagen matrix injection combined with flap repair for complex anal fistula
    P Sileri
    Department of Surgery, University of Rome Tor Vergata, Policlinico Tor Vergata, Rome, Italy
    Colorectal Dis 14:24-8. 2012
    ..We report our experience with this two-staged procedure on 24 consecutive patients with complex anal fistulae with a median follow up of > 12 months. In our experience this two-stage approach seems to be safe and effective...
  69. ncbi Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3
    Roberta Caruso
    Department of Internal Medicine and Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University Tor Vergata of Rome, Rome, Italy
    Blood 113:3512-9. 2009
    ..These data indicate that IL-25 is a negative regulator of monocyte proinflammatory cytokine responses, which may have therapeutic implications...
  70. ncbi Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation
    Roberta Caruso
    Department of Internal Medicine and the Centre of Excellence for Genomic Risk Assessment in Multifactorial and Complex Diseases, University Tor Vergata of Rome, Rome, Italy
    Am J Pathol 169:268-78. 2006
    ..These data show that PAR-2 is overexpressed in GC and suggest a role of PAR-2 in EGFR trans-activation and cell growth...
  71. ncbi Role of interleukin-21 in inflammation and allergy
    Daniele Fina
    Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy
    Inflamm Allergy Drug Targets 6:63-8. 2007
    ..As discussed in this review, the potential role of IL-21 in immune-mediated and allergic diseases would seem to suggest that either disrupting or enhancing IL-21 signaling may be useful in specific clinical settings...
  72. ncbi 2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression
    Carmine Stolfi
    Department of Internal Medicine, Universita Tor Vergata, Via Montpellier, 1 00133, Rome, Italy
    Mol Cancer Ther 10:1969-81. 2011
    ..These findings indicate that 2-14 acts as a sensitizer for TRAIL-induced apoptosis and suggest that 2-14 can be useful in the therapy for TRAIL-resistant colon cancer...
  73. ncbi Cytokine therapies in Crohn's disease: where are we now and where should we go?
    Flavio Caprioli
    Dipartimento di Medicina, Interna, Universita Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Inflamm Allergy Drug Targets 10:47-53. 2011
    ..These findings and our better understanding of cytokine-associated effector pathways of tissue destruction suggest the necessity of novel cytokine-based therapies in CD...
  74. ncbi Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases
    Daniela De Nitto
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
    Curr Pharm Des 16:3656-60. 2010
    ....
  75. ncbi Body cell mass measured by bioelectrical impedance spectroscopy in professional football (soccer) players
    G Melchiorri
    Human Movement and Sport Science, Tor Vergata University of Rome, Rome, Italy
    J Sports Med Phys Fitness 47:408-12. 2007
    ..The aim of this study was to measure body cell mass (BCM) in two football (soccer) teams and assess if there are differences in body composition among players of different field positions...
  76. ncbi Interleukin-25 negatively controls pathogenic responses in the gut
    Eleonora Franzè
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier 1, 00133 Roma, Italy
    Inflamm Allergy Drug Targets 10:187-91. 2011
    ..These new and exciting pre-clinical observations suggest that therapeutic interventions aimed at enhancing IL-25 activity could be useful in the management of patients with chronic gut inflammation...
  77. ncbi Targeting interleukin-21 in inflammatory diseases
    Massimiliano Sarra
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
    Expert Opin Ther Targets 15:695-702. 2011
    ..However, one should also take into consideration some potential risks that could derive from the blockade of IL-21...
  78. ncbi 5-aminosalicylic acid enhances anchorage-independent colorectal cancer cell death
    Daniele Fina
    Dipartimento di Medicina Interna, Cattedra di Gastroenterologia, e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, , Via Montpellier, 1, 00133 Rome, Italy
    Eur J Cancer 42:2609-16. 2006
    ..In contrast, the 5-ASA-mediated Colo205 cell death is preventable by Bcl-2 over-expression. These data suggest a mechanism by which 5-ASA interferes with colon carcinogenesis...
  79. ncbi A correlation between knee cartilage degradation observed by arthroscopy and synovial proteinases activities
    Stefano Marini
    Department of Experimental Medicine and Biochemistry Science, University of Rome TorVergata, Rome, Italy
    Clin Biochem 36:295-304. 2003
    ..Results indicate that an imbalance between specific MMP activities and the amount of TIMPs and of its inhibitory efficiency is crucial for the disease evolution and it is related to the disease stage...
  80. ncbi Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells
    Ladislava Sebkova
    Dipartimento di Medicina Sperimentale e Clinica, Università di Catanzaro Magna Graecia, Via T Campanella, 88100 Catanzaro, Italy
    Infect Immun 72:5019-26. 2004
    ..In H. pylori-colonized gastric epithelial cells, IL-17-induced IL-8 synthesis is associated with and depends at least in part on the activation of ERK 1/2 MAP kinase...
  81. ncbi Breast milk lactoferrin regulates gene expression by binding bacterial DNA CpG motifs but not genomic DNA promoters in model intestinal cells
    Peter Mulligan
    Adult and Paediatric Gastroenterology, Institute of Cell and Molecular Science, Barts and The London, Queen Mary's School of Medicine and Dentistry, London E1 2AD, United Kingdom
    Pediatr Res 59:656-61. 2006
    ..We conclude that breast milk LF regulates gene expression by binding CpG motifs extracellularly, with follicular B cells in the infant intestine a likely target...
  82. ncbi Immunity, inflammation, and allergy in the gut
    Thomas T MacDonald
    Division of Infection, Inflammation, and Repair, University of Southampton School of Medicine, Southampton General Hospital, Southampton, SO16 6YD, UK
    Science 307:1920-5. 2005
    ..This suggests that perturbing homeostasis between gut antigens and host immunity represents a critical determinant in the development of gut inflammation and allergy...
  83. ncbi Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7
    Massimo C Fantini
    Laboratory of Immunology, I Medical Clinic, Johannes Gutenberg University of Mainz, Mainz, Germany
    J Immunol 172:5149-53. 2004
    ..In summary, we demonstrate that TGF-beta induces a regulatory phenotype in CD4(+)CD25(-) T cells through the induction of Foxp3 and a positive autoregulatory loop of TGF-beta signaling due to the absence of Smad7...
  84. ncbi Activated STAT4 and a functional role for IL-12 in human Peyer's patches
    Giovanni Monteleone
    Division of Infection, Inflammation, and Repair, University of Southampton School of Medicine, Southampton General Hospital, Southampton, United Kingdom
    J Immunol 170:300-7. 2003
    ..These data show that IL-12 in human PP is likely to be responsible for the Th1-dominated cytokine response of the human mucosal immune system...
  85. ncbi Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha
    Björn Lamprecht
    Max Delbruck Center for Molecular Medicine, Berlin, Germany
    Blood 112:3339-47. 2008
    ..Together, these data support the concept that aberrant expression of B lineage-inappropriate genes plays an important role for the biology of HL tumor cells...
  86. ncbi Matrix metalloproteinases in necrotising enterocolitis
    Sylvia Lin Foon Pender
    Division of Infection, Inflammation and Repair, Mailpoint 813, Level E, South Academic Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK
    Pediatr Res 54:160-4. 2003
    ..These results suggest that stromelysin-1, which has the ability to degrade the mucosal extra-cellular matrix, may be responsible for the extensive tissue injury in infants with NEC...
  87. ncbi Constitutive activation of the signal transducer and activator of transcription pathway in celiac disease lesions
    Giuseppe Mazzarella
    Istituto di Scienze dell Alimentazione, Consiglio Nazionale delle Ricerche, Avellino, Italy
    Am J Pathol 162:1845-55. 2003
    ..Furthermore, inhibition of STAT-1 prevented the gliadin-mediated induction of ICAM-1 and B7-2. These data suggest that persistent STAT-1 activation can contribute to maintaining and expanding the local inflammatory response in CD...
  88. ncbi Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies
    Antonio Di Sabatino
    Centre for Infectious Disease, Institute of Cell and Molecular Science, Barts and The London Queen Mary s School of Medicine and Dentistry, London, United Kingdom
    Gastroenterology 133:137-49. 2007
    ..We investigated the action of infliximab on apoptosis, the production of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMP)-1, and migration of Crohn's disease (CD) myofibroblasts...
  89. ncbi Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells
    Sabine Dominitzki
    Laboratory of Immunology, Medical Clinic I, University of Mainz, Mainz, Germany
    J Immunol 179:2041-5. 2007
    ....
  90. ncbi Enhanced expression of interferon regulatory factor-1 in the mucosa of children with celiac disease
    Virginia M Salvati
    Department of Pediatrics and European Laboratory for the Investigation of Food Induced Diseases, University Federico II, Naples, Italy
    Pediatr Res 54:312-8. 2003
    ....
  91. ncbi Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication
    Ilaria Peluso
    World J Gastroenterol 12:5606-10. 2006
    ....
  92. ncbi Emerging role of IL-23/IL-17 axis in H pylori-associated pathology
    Roberta Caruso
    World J Gastroenterol 13:5547-51. 2007
    ..In this paper, we will review the available data on the expression and role of IL-23 and IL-17 in H pylori-related gastritis...
  93. ncbi Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease
    Antonio Di Sabatino
    Centre for Infectious Disease, Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    Gastroenterology 133:1175-87. 2007
    ..We examined mucosal DCs in celiac disease in terms of phenotype, activation/maturation state, cytokine production, and function...
  94. ncbi Interleukin-12 drives the Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa
    Antonia Pellicanò
    Dipartimento di Medicina Sperimentale e Clinica, Università di Catanzaro Magna Graecia, Campus Universitario di Germaneto, Viale Europa, 88100 Catanzaro, Italy
    Infect Immun 75:1738-44. 2007
    ..Our data indicated that IL-12 contributes to the Th1 cell commitment in H. pylori-infected human gastric mucosa...
  95. ncbi Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid
    Carmine Stolfi
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1 00133 Rome, Italy
    Biochem Pharmacol 75:668-76. 2008
    ..Taken together our data indicate that 5-ASA causes both a COX-2-dependent and -independent inhibition of CRC cell growth...
  96. ncbi Compartmentalised expression of meprin in small intestinal mucosa: enhanced expression in lamina propria in coeliac disease
    Daniel Lottaz
    Institute of Biochemistry and Molecular Medicine, University of Bern, CH 3012 Bern, Switzerland
    Biol Chem 388:337-41. 2007
    ..Meprin thereby gains access to the substrate repertoire present beneath the epithelium...